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Abstract 14 
Zebrafish Mate7 belongs to solute carrier protein superfamily and specifically to subfamily of multidrug and 15 
toxin extruders. It is co-orthologous to mammalian Mates, and is ubiquitously expressed in zebrafish tissues 16 
with the highest expression in kidney. It has been shown to interact with both endogenous (steroid hormones) 17 
and xenobiotic compounds (pharmaceuticals), implying its role in efflux of toxic compounds. The objective of 18 
our study was to analyse interaction of environmental contaminants with zebrafish Mate7 using a newly 19 
developed high throughput screening (HTS) Mate7 assay. A full-length zebrafish mate7 sequence was obtained 20 
from zebrafish cDNA originating from male kidney, and a stable expression of Mate7 in genetically engineered 21 
HEK293 Flp-In cells was achieved. Stable Mate7 transfectants were then used for development and 22 
optimization of a new HTS cellular uptake protocol, with DAPI and ASP+ as model fluorescent substrates. The 23 
developed assay was used for identifying zebrafish Mate 7 interactors and discerning the type of interaction. 24 
A series of 89 diverse environmental contaminants, including industrial chemicals, pesticides, and 25 
pharmaceuticals, was tested and highly effective Mate7 interactors were identified in all of the 26 
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aforementioned groups. Some of the inhibitors identified could be of environmental concern because they 27 
may potentially impair Mate7 efflux function, lowering the fish defence capacity against environmental 28 
contaminants, or interfering with transport of yet unidentified physiological substrates. In addition, we found 29 
significant differences between zebrafish Mate7 and mammalian Mates’ substrate preferences, a finding that 30 
should be taken into consideration when using zebrafish as a model organism in toxicokinetics studies.  31 
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Trafficking of compounds through cells and tissues is significantly determined by passive diffusion and active 35 
uptake and efflux. After a xenobiotic compound has entered the cell it is metabolized by phase I and II 36 
detoxification enzymes and eventually eliminated from the cell via efflux transporters. MATE (multidrug and 37 
toxin extrusion) proteins, together with ABC transporters have been shown to constitute an important part of 38 
the mammalian cellular detoxification system. They function as efflux transporters that mediate 39 
predominantly the elimination of cationic compounds (e.g., metformin, cimetidine, MPP+, TEA) but can also 40 
transport anionic (E3S) and zwitterionic (e.g., cephalexin, cefradine) compounds (Damme et al., 2011).  41 
MATE/Mate proteins (MATEs in humans and mice, Mates in all other species; gene name SLC47 in humans, 42 
Slc47 in mice, and slc47 in all other species) belong to the superfamily of solute carriers (SLCs). They function 43 
as bidirectional transporters, with the efflux of substrates linked to the proton-coupled electroneutral 44 
exchange (Tsuda et al., 2007). MATEs/Mates are 400–600 amino acids long and consist of 12–13 45 
transmembrane domains (TMDs) with an intracellular N terminus and intracellular or extracellular C terminus 46 
(Zhang and Wright, 2009; Zhang et al., 2012). There are three functional MATE proteins in humans (MATE1, 47 
MATE2 and MATE2-K) (Otsuka et al., 2005; Masuda et al., 2006), two in mice (MATE1a and MATE2) (Hiasa et 48 
al., 2006; Hiasa et al., 2007; Kobara et al., 2008), rats (Mate1 and Mate2) (Ohta et al., 2006; Hiasa et al., 2007), 49 
and rabbits (Mate1 and Mate2-K) (Zhang et al., 2007). 50 
In our previous work we have shown that zebrafish (Danio rerio) has 6 mate genes grouped in two clusters of 51 
3 genes each that probably arose through teleost specific whole genome duplication (Loncar et al., 2016). 52 
Zebrafish mate clusters are co-orthologous to human MATEs, but 1:1 cluster to gene orthology could not be 53 
determined since zebrafish mates are more similar within the group than with either of human MATEs. Mates 54 
are expressed in developing zebrafish embryos and in the tissues (kidney, liver, intestine, brain, gonads, gills 55 
and eye) of adult individuals where they interact with both physiological (steroid hormones, thiamine) and 56 
xenobiotic (pharmaceuticals, pesticides) compounds (Loncar et al., 2016). Although zebrafish is an emerging 57 
model in both clinical and in environmental pollution research, studies on interaction of zebrafish Mates with 58 
xenobiotics are still scarce. Therefore, in this study we aimed at testing a wide range of xenobiotic substances 59 
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(industrial chemicals, pesticides, and pharmaceuticals) for their interaction with Mate7 as potentially 60 
ecotoxicologically important fish efflux transporter. Mate7 was shown to be present in embryos and in adult 61 
zebrafish likewise, with notably high expression of mate7 transcripts in kidney and brain of adult fish, as well 62 
as in the early embryonic stages. Furthermore, it has been shown to transport multiple cationic dyes, and 63 
interact both with endo- and xenobiotics (Loncar et al., 2016). To efficiently address the main goal of the study, 64 
we have firstly developed a stable Mate7 over-expressing HEK293 Flp-In cell line. Next, to obtain a high 65 
throughput screening (HTS) assay a previously developed cellular uptake protocol was further modified. A 66 
series of 89 substances, selected on the basis of their occurrence in surface waters and/or reported interaction 67 
with mammalian Mates (Fent et al., 2006; Murray et al., 2010; Ivanyuk et al., 2017), were then screened for 68 
interaction with zebrafish Mate7. Compounds that showed significant interaction potency, determined as 69 
inhibition of the model fluorescent substrate (DAPI) uptake, were further characterized for the type of 70 
interaction, i.e. whether they are substrates or inhibitors of zebrafish Mate7.  Finally, interaction specificities 71 
of mammalian versus zebrafish Mate7 were discussed. 72 
 73 
Materials and Methods 74 
Chemicals 75 
All tested compounds, model fluorescent substrates and interactors alike, were purchased from Sigma-Aldrich 76 
(Taufkirchen, Germany) or Alfa Aesar (Ward Hill, MA, USA) unless stated otherwise. 77 
Cloning and development of the Mate7-expressing cell line 78 
A full-length zebrafish mate7 sequence (NM_001302254.1) was obtained from zebrafish cDNA originating 79 
from male kidney by polymerase chain reaction using high fidelity Phusion DNA polymerase (Finnzymes, 80 
Vantaa, Finland) and specifically designed primers with HindIII and EcoRI restriction sites in the forward, and 81 
NotI and SmaI restriction sites in the reverse primer. An amplified DNA fragment was cloned into a 82 
pcDNA3.1/His vector (Thermo Fisher Scientific, Waltham, USA) linearized with combination of restriction 83 
enzymes HindIII/NotI that also excised the His tag sequence from the vector. The sequence was verified by 84 
DNA sequencing using automated capillary electrophoresis (ABI PRISM® 3100-Avant Genetic Analyzer) at the 85 
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Ruđer Bošković Institute DNA Service (Zagreb, Croatia). Three gene clones were sequenced and compared to 86 
the reported gene sequences from the NCBI and ENSEMBL databases. The verified mate7 sequence was used 87 
for further subcloning. 88 
A stable expression of Mate7 in genetically engineered HEK293 Flp-In cells (Thermo Fisher Scientific, Waltham, 89 
USA) was achieved using targeted integration of the mate7 sequence subcloned into integration vector 90 
pcDNA5/FRT (Thermo Fisher Scientific, Waltham, USA) with combination of restriction enzymes HindIII/XhoI. 91 
pcDNA5/FRT/Mate7 constructs were specifically targeted into the genome of the Flp-InTM-293 cells following 92 
the manufacturer’s instructions. In short, 375 ng of the pcDNA5/FRT/Mate7 construct was co-transfected with 93 
the helper plasmid pOG44 in a 1:9 ratio (3,375 ng of DNA) with polyethylenimine (PEI) as transfection reagent 94 
(PEI:DNA = 1:1) in the cells seeded 48 h before transfection in a 6-well plate at concentration 7.5 x 105 95 
cells/well. After 48 h, the cells were transferred (without trypsinization) to a 25 cm2 cell culture flask and grown 96 
in Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine serum. Cells were left to attach 97 
overnight. Hygromycin B was added in the morning to the final concentration of 100 µg/ml. The medium was 98 
changed every 3-4 days and hygromycin B selection continued until single colonies appeared (after 99 
approximately 25-30 days). Finally, Mate7 stable transfectants were functionally verified by determination of 100 
the uptake rate of model fluorescent substrates in comparison to mock-transfected cells. 101 
Cellular uptake experiments 102 
The cellular uptake experiments with FlpIn/Mock and FlpIn/drM7 cells were performed in 96-well plates. The 103 
cells were seeded in high glucose DMEM supplemented with 10% FBS, at density sufficient to reach confluence 104 
after 48 h cultivation (75,000 cells/well) after which the uptake assay was performed as follows. The medium 105 
was aspired and 100 µL (for inhibition assays) or 125 µL (for dye uptake determinations) of Na-based transport 106 
buffer (145 mM NaCl, 3 mM KCl, 1 mM CaCl2, 0.5 mM MgCl2, 5 mM glucose and 5 mM Hepes or 10 mM Tris, 107 
pH 7.4 or 8.4) was added. For determination of the uptake of fluorescent model substrates, 25 µL of dye 108 
solution was added to the reaction mixture to reach the desired final concentration. In the case of DAPI and 109 
ASP+, real time uptake kinetics were then monitored for 5-10 minutes. As uptake kinetics of Rh123, amiloride 110 
and berberine cannot be measured in real time, 5 min uptake accumulation was determined after the uptake 111 
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of dye was stopped by rapid washing (2x) with ice cold PBS, followed by the cells lysis with 0.1% SDS for 30 112 
min.  113 
For intracellular acidification experiments, the cells were incubated for 20 minutes with 100 µL/well of 20 mM 114 
NH4Cl which was aspired prior to dye uptake measurement carried out as described above. Fluorescent signals 115 
for various model substrates were read at following excitation and emission wavelengths: DAPI, 360/460 nm; 116 
ASP+, 450/590 nm; Rh123, 485/530 nm; berberine, 355/540 nm; amiloride, 366/418 nm. The uptake into 117 
mock-transfected cells that received empty vector was subtracted to obtain transporter-specific uptake. 118 
The calibration curve for DAPI was obtained in the presence of a cell matrix or pure DNA generating similar 119 
curves. Calibration curves for all other substrates were generated in 0.1% SDS and in the cell matrix dissolved 120 
in 0.1% SDS, except for ASP+ where cell matrix without detergent was used. Resulting linear calibration curves 121 
were the same in the SDS (where applied) and in the dissolved cell matrix. Using the obtained calibration 122 
curves, corresponding uptake rates (uptake velocities) were expressed as pmol of substrate per mg of protein 123 
per minute. Total cell protein content was determined according to the Bradford method. 124 
Inhibition assays using DAPI or ASP+ as fluorescent substrates were performed in the same transport medium 125 
as for the substrate uptake experiments. The applied concentrations of both DAPI and ASP+ were 2 μM. Taking 126 
into consideration their solubility in water, the compounds tested for interaction were initially tested at 127 
concentration of 100 µM unless stated otherwise. When interacting compounds showed inhibition of DAPI 128 
uptake above 30%, which was set as an arbitrary threshold that indicates significant interaction, their 129 
concentration-response curves were obtained, and related IC50 values were determined. Compounds with IC50 130 
of < 1 μM were designated as very strong (VSt) interactors, IC50 of 1-29 μM indicated strong (St) interaction 131 
strength, interactors with IC50 of 30-99 μM were designated as moderate interactors, IC50 of 100-999 μM was 132 
classified as weak interaction strength, and interactors with IC50 above 1,000 μM were considered as very 133 
weak interacting substances. 134 
To determine type of interaction for Mate7 interacting compounds, shift in Km and Vmax values for DAPI in the 135 
presence of interacting compound (at the concentration equal to the IC50 value of the compound) at varying 136 
concentrations of DAPI was measured. Experiments done in triplicate were repeated at least three times and 137 
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the uptake into mock cells was subtracted to obtain the transporter specific uptake. DAPI uptake followed 138 
Michaelis-Menten type kinetics, where Km increase and no change in transport rate in presence of an 139 
interactor indicated competitive inhibition (i.e. the substance is identified as a substrate). Contrary to that 140 
pattern, no change in Km and Vmax decrease indicated non-competitive inhibition. Substrate affinity (Km) was 141 
considered to be very high for Km < 1 μM, high for Km 1-29 μM, moderate for Km 30-99 μM, and low for Km > 142 
100 μM. 143 
Cytotoxicity assays 144 
Cytotoxicity was determined using the MTT reduction assay adapted according to the Mosmann's procedure 145 
(Mosmann, 1983). The FlpIn/Mock and FlpIn/drM7 cells were seeded in 96-well plates and exposed to a range 146 
of concentrations of tested chemicals for 72 h, except for the rescue experiments were cells were exposed for 147 
1 hour. Tested compounds were then removed, the cells washed in PBS and incubated for 72 h in DMEM 148 
supplemented with 10% FBS. Subsequently, the medium was removed and the cells were incubated for 3 h 149 
with 0.5 mg/ml MTT (100 μl/well) dissolved in DMEM. The formazan salts were dissolved in isopropanol (15 150 
min with shaking) and the absorbance was read at 578 nm using 750 nm as a reference wavelength. 151 
Cytotoxicity was expressed as the percentage of product formed by mitochondrial activity with respect to the 152 
corresponding control (untreated cells) level. 153 
Data analysis 154 
All assays were performed in 3-5 independent experiments run in triplicates. Data shown 155 
on related figures represent mean ± standard errors (SE) or standard deviations (SD). All calculations were 156 
performed using GraphPad Prism 5.0 for Windows (GraphPad Software, San Diego, California, USA) as 157 
described below. The kinetic parameters, Km and Vmax values were calculated using the Michaelis-Menten 158 
equation (1): 159 







where V is velocity (picomoles of substrate per milligram of proteins per minute), Vmax is maximal velocity, [S] 162 
is substrate concentration and Km is the Michaelis-Menten constant. The uptake into vector-transfected 163 
HEK293 cells was subtracted to obtain transporter-specific uptake.  164 
For the purpose of IC50 calculations, data were fitted to the sigmoidal four-parameter dose-response model 165 
(variable slope), according to equation (2): 166 
 167 





where V is response, Vmin represents minimum of response, Vmax represents maximum of response, h is Hill 170 
slope parameter, IC50 is the concentration of inhibitor that corresponds to 50% of maximal effect, and A is 171 
the concentration of a tested compound. 172 
 173 
Results 174 
Kinetic parameters of Mate7 fluorescent substrates 175 
Basic kinetic parameters were obtained for five fluorescent Mate7 substrates. The uptake of all five substrates 176 
followed the classical Michaelis-Menten kinetics and the obtained values (Table 1) are in good correlation with 177 
results obtained using the transient assay system (Loncar et al., 2016). However, only DAPI and ASP+ were 178 
selected as model fluorescent zebrafish Mate7 substrates for further experiments in this study as they enable 179 
real time uptake measurements more suitable for HTS requirements (Fig. 1).  180 
 181 
Table 1. Kinetic parameters, Km (μM) and Vmax (pmol/mg protein/min) of the zebrafish Mate7 mediated 182 
uptake of fluorescent dyes.  DAPI – 4′,6-diamidino-2-phenylindole; ASP+ – 4-(4-(dimethylamino)styryl)-N-183 
methylpyridinium iodide;  Rh123 – rhodamine 123. Each value represents mean from at least three 184 
independent experiments with 95% confidence intervals (ci) stated. Related dose-response curves are shown 185 




Km (µM) 95% ci 
Vmax 
(pmol/min/mg) 
95% ci N 
DAPI 1.46 1.13-1.79 1092 1010-1174 27 
ASP+ 0.98 0.48-1.48 58.3 49.8-66.8 4 
Rh123 0.29 0.14-0.45 8.14 6.70-9.58 3 
Amiloride 3.02 0.99-5.06 20.9 16.7-25.0 4 
Berberine 0.91 0.34-1.50 24.3 20.0-28.5 5 
 187 
 188 
Probing the Mate7 substrate binding site  189 
Kinetic experiments performed with varying concentrations of DAPI or ASP+ in the presence of other known 190 
fluorescent substrates showed that type of interaction in all combinations was a competitive inhibition (Figs. 191 
2 and S2, and Tables 2 and S1). Accordingly, toxicity experiments (Table 3) clearly confirmed that Mate7 stable 192 
transfectant cells were more sensitive to toxic effects of the substrates applied than mock cells, due to the 193 
Mate7 active transport of respective substrates. Altogether, these data show that all dyes are transported 194 
through one and the same Mate7 binding site. 195 
 196 
  197 
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 202 
Figure 1. Michaelis-Menten kinetics of the uptake of fluorescent dyes 4',6-diamidino-2-phenylindole (DAPI), 203 
and 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP+) by zebrafish Mate7. A – time course of 204 
DAPI cellular accumulation; B –  concentration dependence of DAPI uptake during 3-4 minutes of kinetic 205 
measurement; C – time course od ASP+ cellular accumulation; D – concentration dependence of ASP+ uptake 206 
during 3 minutes of kinetic measurement. The uptake into HEK293 Flp-In cells (mock cells) was subtracted to 207 
obtain transporter-specific uptake. Each value represents the mean + SE from at least three independent 208 
experiments.  209 
 210 
 211 




























































































Table 2. Determination of the type of interaction with DAPI as substrate and fluorescent dyes as interactors. 212 
Kinetic parameters of DAPI uptake are given as apparent Km (Km,app) and apparent Vm (Vm,app) with 95% 213 
confidence intervals (ci). A representative example of at least three independent experiments, each done in 214 
triplicate, is shown. For the IC50 calculations data from at least three independent experiments were fitted to 215 















DAPI NA NA 0.96 0.59-1.33 963 852-1075 NA 
ASP+ 7.10 5.88-8.48 3.41 1.79-5.01 948 729-1166 S 
Rh123 0.23 0.22-0.25 1.75 1.40-2.10 820 758-885 S 
Berberine 0.82 0.75-0.90 1.70 1.37-2.03 1007 937-1077 S 
TOI – type of interaction; S – substrate; NA – not applicable 217 
 218 
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Figure 2.  Concentration dependent inhibition (A-C) and determination of the type of interaction (D-F) of 225 
Mate7 mediated 4',6-diamidino-2-phenylindole (DAPI) uptake by fluorescent dyes ASP+ (A, D), Rh123 (B, E), 226 
and Berberine (C, F). The specific uptake of 2 µM DAPI is expressed as percentage relative 227 
to the DAPI uptake in the absence of an interactor (which is set to 100 %). Determination of the type of 228 
interaction was done through comparison of apparent kinetic parameters (Km,app; Vm,app) of inhibited (IC50 value 229 
of respective fluorescent dye) versus uninhibited (control) reaction obtained by measuring uptake of 230 
increasing concentrations of DAPI. Each data point for A, B and C represents the mean ± SE from at least three 231 
independent experiments, while for D, E and F each data point is a mean ± SD from triplicate of a 232 
representative of at least three independent experiments. 233 
 234 
Table 3. Determination of the type of interaction and sensitivity factors through modulation of cytotoxicity 235 
of Mate7 fluorescent substrates.  Discrimination of the type of interaction (TOI) and calculation of sensitivity 236 
factors (SF) is based on the assumption that stably transfected Mate7 cells are more sensitive to toxic effects 237 
of the substrates applied, as determined by the MTT assay, in comparison to mock cells due to the Mate7 238 
active transport of respective substrates inside of the cells. For the EC50 calculations, data from a 239 
representative experiment (done in triplicate) out of at least three independent experiments were fitted to 240 
the sigmoidal four-parameter dose-response model (variable slope) in GraphPad Prism version 5.  241 
 mock drM7   
 
EC50 
[µM] 95% ci 
EC50 
[µM] 95% ci TOI SF 
ASP+ 7.57 5.92 - 9.67 2.30 1.84 - 2.86 S 3.3 
Rh123 1.58 0.98-2.52 0.46 0.36-0.57 S 3.5 
Berberine 16.5 7.34-36.9 2.95 1.29-6.71 S 5.6 
DAPI 3.65 2.33-5.72 0.17 0.14-0.21 S 21.4 
TOI – type of interaction; ci – confidence intervals; SF – sensitivity factor calculated as 242 
a ratio of EC50 values obtained for mock versus Mate7 transfected cells 243 
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Interaction of xenobiotic compounds with Mate7 244 
A total of 89 chemicals were initially screened for interaction with zebrafish Mate7 (Fig. 3). Compounds were 245 
selected on the basis of their occurrence in surface waters, and/or reported interaction with mammalian 246 
Mates, and/or common usage in medical treatments. Substances (30 compounds) that showed DAPI uptake 247 
inhibition of at least 30% were further analysed to obtain IC50 values and to determine their type of interaction 248 
with zebrafish Mate7 (Table 4). Type of interaction is further supported with toxicity data, as summarized in 249 
Table 5. 250 
Industrial chemicals 251 
Very strong (TPenA), strong (TBA) and moderate (TPrA) interaction with zebrafish Mate7 was obtained for 252 
quaternary ammonium salts. TPenA is a strong non-competitive inhibitor (Table 4 and 5) while TPrA and TBA 253 
are moderate and strong competitive inhibitors with IC50 values of 60 µM and 6 µM, respectively. 254 
Organotin compounds were shown to be strong to moderate non-competitive inhibitors with IC50 values of 255 
60, 11 and 71 µM for triethyltin, tripropyltin and tributyltin, respectively (Table 4). Type of interaction for 256 
organotins was further supported with toxicity assay results, i.e. no difference in toxicity response has been 257 
obtained in transfected versus mock transfected cells upon exposure to organotins (Table 5). Bisphenol A 258 
showed moderate non-competitive inhibition of zebrafish Mate7 uptake. Selected antioxidant, phthalates, 259 
perfluorates and triazole did not show interaction with Mate7 at the chosen concentration of 100 µM under 260 
selected experimental conditions. 261 
Pesticides 262 
Tested pesticides either showed weak interaction (diazinon, atrazine,) or did not show any interaction at the 263 
selected 100 µM concentrations. Although atrazine showed stronger inhibition of DAPI uptake at 100 µM than 264 
diazinon, IC50 value for atrazine could not be obtained due to solubility issues at higher concentrations. 265 
Pharmaceuticals  266 
We have tested a wide range of pharmaceuticals (Figure 3; Table 4 and 5). Most of the tested analgesics, lipid 267 
regulators (except atorvastatin), NSAIDs, hormones (except estradiol) and antiviral agents did not show any 268 
interaction with Mate7 at the initial concentration of 100 µM. Acebutolol and propranolol (both beta blockers) 269 
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showed weak and strong interaction, respectively. They are both competitive inhibitors, together with 270 
ranitidine (H2 blocker), imipramine (antidepressant), DPH (H1 receptor antagonist), procainamide 271 
(antiarrhythmic drug), MPP+, pyrimethamine (antimalarial agent), and doxorubicin (antineoplastic agent). In 272 
the class of competitive inhibitors, propranolol (IC50 20 µM), imipramine (IC50 28 µM), doxorubicin (IC50 14 µM) 273 
and pyrimethamine (IC50 15 µM) showed strong interaction, while all the other competitive inhibitors showed 274 
moderate to weak interaction. All the other interactors – the antibiotic tetracycline; chemotherapeutics 275 
methotrexate and mitoxantrone; the cardiovascular agent sildenafil; the antidepressant fluoxetine; calcium 276 
channel blockers verapamil, quinidine, and diltiazem; the lipid regulator atorvastatin; the hormone estradiol; 277 
and the anti-parkinson agent pramipexole, inihibited DAPI uptake in the non-competitive fashion. 278 
Mitoxantrone, sildenafil, verapamil, quinidine, and pramipexole showed the strong interaction while 279 
tetracycline, fluoxetine and diltiazem elicited moderate interaction. Estradiol, atorvastatin, and methotrexate 280 




      283 
 284 
Figure 3. Interaction of zebrafish Mate7 with selected interactors. Data are expressed as percentage (%) of 285 
4′,6-diamidino-2-phenylindole (DAPI) uptake kinetics after co-incubation with each modulator (100 μM for all 286 
compounds, except for DDE, dieldrin, endosulfan, and methoxychlor which were set to 1 μM; doxorubicin, 287 
prazosin, BHT, DEHP, chlorpyrifos, esfenvalerate, tamoxifen and AHTN that were set to 10 μM; and 288 
gemfibrozil, simvastatin, and indomethacin that were set to 30 μM) relative to DAPI uptake kinetics in the 289 
absence of a modulator, which is set to 100%. Results obtained at both, pH 7.4 (dark bars) and at pH 8.4 (light 290 
bars) are shown. Dotted line represents the inhibition threshold set arbitrarily at 30%. Data represent mean ± 291 
SE from three to five independent experiments (n = 3–5). Abbreviations used:  acetaminophen (APAP), 292 
dichlorodiphenyldichloroethylene (DDE), 2, 4-dichlorophenoxyacetic acid (2, 4-D), tetrapentylammonium chloride 293 
(TPenA), tetrabutylammonium hydrogen sulphate (TBA), tetrapropylammonium chloride (TPrA), tetraethylammonium 294 
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bicarbonate (TEA), tetramethylammonium chloride (TMA), triphenyltin chloride (TPheT), tri-n-butyltin chloride (TBT), tri-295 
n-propyltin chloride (TPrT), triethyltin chloride (TET), Trimethyltin chloride (TMT), diphenyltin dichloride (DPheT), di-n-296 
butyltin dichloride (DBT), dimethyltin dichloride (DMT), n-Butyltin trichloride (BUT), methyltin trichloride (MET), 297 
Benzotriazole (BT), Dibutyl phthalate (DBP), Bis(2-ethylhexyl)phthalate (DEHP), Diethyl phthalate (DEP), bisphenol A 298 
(BPA), Nonylphenol (NP), Perfluorooctanesulfonic acid (PFOS), Perfluorooctanoic acid (PFOA), Butylated hydroxytoluene 299 
(BHT), Diphenhydramine hydrochloride (DPH), p-aminohipuric acid (PAH), 1-methyl-4-phenylpyridinum iodide (MPP+), 300 
N,N-diethyl-meta-tolumide (DEET), 17 a-ethinyl estradiol (EE2), acetyl-hexamethyl-tetrahydro-naphthalene (AHTN). 301 
 302 
 303 
Figure 4. Michaelis-Menten kinetics experiment aimed at determination of the type of interaction. (A) 304 
example of an inhibitor (tetracycline), (B) example of a substrate (procainamide). Determination of the type 305 
of interaction was performed through comparison of apparent kinetic parameters (Km,app; Vm,app) of inhibited 306 
reaction (IC50 value of respective fluorescent dye) versus uninhibited (control) obtained by measuring uptake 307 
of increasing concentrations of DAPI. Each data point represents mean ± SD from triplicate of a representative 308 
experiment out of at least three independent experiments. 309 
 310 
























































Figure 5. Cytotoxicity experiment aimed at determination of the type of interaction. (A) example of an 312 
inhibitor (tetracycline), (B) example of a substrate (ranitidine). Cytotoxicity modulation is based on the 313 
assumption that stable transfected Mate7 cells are more sensitive to toxic effects of the substrates applied, 314 
as determined by the MTT assay, in comparison to mock cells due to the Mate7 active transport of respective 315 
substrates inside of the cells. For the EC50 calculations, data from a representative experiment (done in 316 
triplicate) out of at least three independent experiments were fitted to the sigmoidal four-parameter dose-317 
response model (variable slope) in GraphPad Prism version 5.  318 
 319 
Cytotoxicity modulation - rescue experiment 320 
When Mate 7 cells were coexposed with model substrate i.e. confirmed toxicant (dapi) in combination with 321 
Mate 7 non-competitive inhibitor (verapamil or quinidine) they became 5-10 times more resistant compared 322 
to the cells incubated with toxicant only and without inhibitors. At the same time mock cells did not show 323 
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 334 
Figure 6. Cytotoxicity rescue experiment. (A) Mock cells exposed to substrate (dapi) with or without inhibitors 335 
for 1 hour and then left to grow for the next 71 hours. (B) Mate7 transfected cells exposed to substrate with 336 
or without 100 µM verapamil for 1 hour and then left to grow for the next 71 hours. (C) Mate7 transfected 337 
cells exposed to substrate with or without 100 µM quinidine for 1 hour and then left to grow for the next 71 338 
hours. For the EC50 calculations, data from a representative experiment (done in triplicate) out of at least 339 




In this study we analysed a wide range of environmentally relevant compounds regarding their interaction 344 
with zebrafish Mate7. Most of the tested compounds are widely used and their accumulation in surface water, 345 
sediment or soil could present a danger for the environment. To be able to efficiently identify zebrafish Mate7 346 












































































expressing HEK293 Flp-In cell line, and optimized a high throughput screening (HTS) assay based on a real time 348 
determination of cellular uptake of Mate7 fluorescent model substrates DAPI and ASP+.  349 
To validate the assay we firstly verified that Mate7 indeed has only one binding site, i.e. that different 350 
substrates are going to be transported through the same active site. There have been conflicting reports 351 
concerning binding site of human MATEs. In reports from 2012 and 2013 (Astorga et al., 2012; Martinez-352 
Guererro and Wright, 2013) the authors argue that substrates bind to different binding sites on MATE 353 
transporter surface. That would imply a complex binding region rather than a single binding site. Wittwer et 354 
al. (2013) explained the discrepancies between inhibition profiles of ASP+ and metformin transport in the 355 
same fashion, ascribing it to a substrate specific binding. However, in a report from 2016 (Martinez-Guererro 356 
et al., 2016) where extensive inhibition profiling of 400 compounds with four structurally distinct MATE 357 
substrates was conducted, the authors stated that no systematic influence of substrate structure on inhibitory 358 
efficacy or on the kinetic interaction of the inhibitor with the transporter (human MATE1) was found.  359 
Therefore, to indirectly test the single binding site hypothesis we identified five fluorescent Mate7 substrates 360 
(Table 1) and selected DAPI and ASP+ as model substrates for kinetic profiling of remaining dyes (Tables 2 and 361 
S1, Figs. 2 and S2). Our kinetic determinations (summarized in Tables 2 and S1) indicate that, in agreement 362 
with Martinez-Guererro et al. report (2016) for human MATE1, zebrafish Mate7 also has a single binding site. 363 
This conclusion is further supported with (a) modulation of toxicity experiments performed with the 364 
aforementioned probes (Table 3); and (b) results of the inhibition profiling of the whole set of tested 365 
compounds for DAPI and ASP+ uptake inhibition that showed high correlation (R = 0.82, Figure S3). Therefore, 366 
we showed that there is only one zebrafish Mate7 binding site, and this finding enables discrimination of the 367 
type of interactors using Michaelis-Menten kinetics experiments based on the developed uptake assay 368 
protocol. 369 
Secondly, it is important to note that MATEs are bidirectional transporters with direction of transport 370 
determined by pH gradient. This means that manipulation of the pH gradient can change the direction of 371 
transport from efflux to uptake. Most of the interaction studies done on MATEs were based on measurement 372 
of the uptake with gradient established either by intracellular acidification or extracellular alkalinisation 373 
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(Masuda et al., 2006; Tsuda et al., 2007; Tanihara et al., 2007; Grottker et al., 2011). Furthermore, it has been 374 
shown that some substrates including DAPI (Yasujima et al., 2010) and TEA (Otsuka et al., 2005; Ohta et al., 375 
2006; Masuda et al., 2006) are transported even without pH gradient. Therefore we have compared transport 376 
rates for DAPI and ASP+ with and without intracellular acidification. Since significant differences in transport 377 
rate in favour of intracellular acidification were not observed (Figure S8), we decided to proceed without 378 
methodologically more complex intracellular acidification, but with two extracellular pHs (7.4 and 8.4, 379 
respectively) to be able to identify a broader scope of potential interactors. 380 
We have tested more than 20 industrial chemicals most of which have not been checked for mammalian or 381 
teleost Mate interaction, and identified several potent interactors (Figure 3, Tables 4 and 5). Organotins are 382 
widely used industrial chemicals present in environment in nanomolar concentrations (Cole et al., 2015). 383 
Mihaljević et al. (2017) found organotins to be strong interactors of zebrafish Oct1 uptake transporter with 384 
IC50 values for DBT, TPrT and TBT in low µM range. We have observed similar interaction potency with Mate7 385 
for TPrT (IC50 11 µM), while TBT was less potent (IC50 71 µM) and no interaction up to 100 µM was determined 386 
for DBT. It appears that organotins have higher affinity for Oct1 than for Mate7, as was further supported by 387 
our cytotoxicity modulation experiments which showed that organotins are not transported by Mate7 (Table 388 
4 and 5; Fig S6 and S7).  389 
 390 
Table 4. Type of interaction analysis with DAPI as substrate and set of chosen compounds as interactors. 391 
Kinetic parameters of DAPI uptake are given as apparent Km (Km,app) and apparent Vm (Vm,app) with 95% ci 392 
(confidence intervals). Data from a representative of at least three independent experiments, each done in 393 
triplicate, are shown. For the IC50 calculations data from at least three independent experiments were fitted 394 
to the sigmoidal four parameters dose-response model (variable slope) in the GraphPad Prism 5. Experiments 395 
were done at either pH 7.4 or 8.4, as indicated (control), and all the chemicals listed under their respective 396 
control values were tested at the same pH. Substances that showed strong or very strong interaction were 397 
typed in boldface.  398 
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Control, pH 8.4 - - 0.96 0.59-1.33 963 852-1075 - 
Bisphenol A 221 165-295 0.80 0.43-1.16 572 497-647 I / W 
Atrazine ND       
Diazinon 173 145-207 4.35 3.27-5.40 1549 1356-1741 S / W 
Tetracycline 33.2 27.0-40.8 1.47 0.59-2.34 729 582-876 I / M 
Pramipexole 20.8 17.9-24.2 1.80 1.11-2.47 549 473-623 I / St 
Procainamide 268 214-336 6.28 5.21-7.35 1314 1194-1433 S / W 
Acebutolol 134 114-157 4.87 3.60-6.13 1012 881-1141 S / W 
Sildenafil 12.9 9.79-17.0 0.51 0.29-0.72 263 236-288 I / St 
Ranitidine 146 127-169 8.30 4.26-12.2 1126 807-1446 S / W 
Fluoxetine 57.9 42.0-79.7 0.87 0.39-1.34 299 243-354 I / M 
Propranolol 19.7 17.4-22.3 3.46 2.32-4.58 1272 1086-1458 S / St 
Methotrexate 80.5 71.9-90.2 1.31 0.93-1.68 354 321-386 I / M 
MPP+ 77.1 66.3-89.6 3.99 2.76-5.21 895 766-1022 S / M 
Verapamil 3.05 2.43-3.82 0.82 0.61-1.00 508 474-541 I / St 
Quinidine 6.03 4.85-7.50 1.23 0.83-1.62 645 579-709 I / St 
Mitoxantrone 3.95 3.53-4.41 1.26 0.88-1.64 561 504-617 I / St 
Imipramine 27.8 23.7-32.6 3.01 1.70-4.32 1025 834-1215 S / St 
Diltiazem 50.9 39.0-66.4 0.65 0.39-0.91 369 328-409 I / M 
DPH 61.4 55.1-68.5 4.01 3.16-4.82 1192 1077-1307 S / M 
TPrA 59.9 52.0-69.1 2.96 1.84-4.06 789 664-915 S / M 
TBA 6.14 5.00-7.54 2.09 1.48-2.68 912 811-1011 S / St 
TPenA 0.59 0.53-0.65 1.62 1.40-1.83 472 450-493 I / VSt 
TET 60.3 50.8-71.7 0.53 0.19-0.85 462 389-535 I / M 
TPrT 11.0 9.26-13.0 0.76 0.11-1.40 462 306-617 I / St 
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TBT 70.7 57.7-86.7 0.17 0.00-0.60 160 60-258 I / M 
Control, pH 7.4 - - 1.15 0.92-1.37 695 652-738 - 
Estradiol 258 198-337 1.23 1.01-1.45 512 482-543 I / W 
Atorvastatin 117 99.3-137 1.22 0.79-1.65 523 460-586 I / W 
Pyrimethamine 14.9 12.4-18.0 5.18 3.15-7.21 915 734-1097 S / St 
TPheT ND       
Doxorubicin 14.4 10.2-20.3 2.85 2.25-3.46 658 587-728 S / St 
ND – not determined; I – inhibitor; S – substrate; W – weak strength interaction; M – moderate strength;  399 
St – strong interaction; VSt – very strong interaction 400 
 401 
We also tested n-tetraalkylammonium compounds, a subgroup of quaternary ammonium compounds (QACs) 402 
which are known model cation substances. However, TEA which is considered a model Mate(s) cationic 403 
substrate did not show any interaction with zebrafish Mate7, in accordance with our previous data that 404 
revealed TEA IC50 value in milimolar range. It has also been shown that TEA, TPrA and TBA are transported by 405 
human OCT1 while TPenA inhibits transporters activity but is not transported itself (Zhang et al., 1999). This is 406 
in line with our finding that TPrA and TBA are transported by Mate7 while TPenA is not. 407 
In general, environmental concentrations of tested industrial compounds are at least 1,000 times lower than 408 
concentrations that we experimentally found to inhibit zebrafish Mate7 transport function. That would imply 409 
that industrial compounds that showed significant interaction with Mate7 are probably not environmentally 410 
relevant. However, this assumption is valid only if bioaccumulation processes in organisms that are chronically 411 
exposed to high concentrations of contaminants are not considered. E.g., although there is no evidence of 412 
biomagnification of tributyltin in marine ecosystems, accumulation may occur, resulting in high tissue 413 
concentrations in some organisms (Meador, 2000). Reported bioconcentration factors for TBT in freshwater 414 
green algae, round crucian carp, tilapia and mollusks were 30,000 (Maguire et al., 1984), 5,000 (Tsuda et al., 415 
1986), 12,300 (Hongxia et al., 1998), and 17,000-350,000 (Gomez-Ariza et al., 2001), respectively (USDHHS, 416 
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2005). If these bioconcentration factors are taken into consideration, affinities of organotins for Mate7, 417 
determined in this study in lower µM range, are sufficient to modulate/disrupt the transporter’s efflux activity.  418 
 419 
Table 5. Determination of the type of interaction through modulation of cytotoxicity of Mate7 interactors.  420 
Type of interaction (TOI) discrimination and calculation of sensitivity factors (SF; calculated as a ratio of EC50 421 
values obtained for mock versus Mate7 transfected cells) is based on the assumption that stable transfected 422 
Mate7 cells are more sensitive to toxic effects of the substrates applied, as determined by the MTT assay, in 423 
comparison to mock cells due to the Mate7 active transport of respective substrates inside of the cells. For 424 
the EC50 calculations, data from a representative experiment (done in triplicate) out of at least three 425 
independent experiments were fitted to the sigmoidal four-parameter dose-response model (variable slope) 426 
in GraphPad Prism version 5. 427 







95% ci SF TOI 
Bisphenol A 112 101-124 106 62.8-178 1.1 I 
Atrazine ND      
Diazinon not tox  not tox   - 
Estradiol 20.7 18.5-23.2 25.7 22.6-29.2 0.8 I 
Tetracycline 97.1 88.8-106 91.3 82.8-100 1.1 I 
Pramipexole 893 833-957 844 480-1482 1.1 I 
Procainamide not tox  not tox   - 
Acebutolol not tox  not tox   - 
Sildenafil 185 152-226 222 189-261 0.8 I 
Ranitidine 1130 894-1427 322 250-414 3.5 S 
Fluoxetine 24.0 20.5-28.1 26.5 24.4-28.5 0.9 I 
Propranolol not tox  not tox   - 
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Methotrexate 0.02 0.01-0.03 0.024 ND 0.8 I 
Doxorubicin 2.56 2.23-2.94 1.13 1.00-1.27 2.3 S 
Atorvastatin 3.68 3.07-4.42 4.55 3.83-5.42 0.8 I 
MPP+ 147 96.0-224 38.9 33.3-45.3 3.8 S 
Pyrimethamine not tox  not tox   - 
Verapamil 95.0 80.5-112 70.1 55.9-87.7 1.4 I 
Quinidine 77.9 72.2-84.0 73.0 53.6-99.2 1.1 I 
Mitoxantrone 0.24 0.14-0.37 0.22 0.18-0.24 1.1 I 
Imipramine not tox  not tox   - 
Diltiazem 53.7 44.9-64.1 42.6 23.4-77.2 1.3 I 
DPH not tox  not tox   - 
TPrA 828 420-1634 115 83.6-158 7.2 S 
TBA 211 138-323 40.1 30.8-52.1 5.3 S 
TPenA 3.03 2.57-3.57 2.34 1.79-3.05 1.3 I 
TET 7.89 7.18-8.69 6.26 5.22-7.50 1.3 I 
TPrT 0.18 0.17-0.19 0.15 0.14-0.16 1.2 I 
TBT 0.30 0.20-0.42 0.21 0.15-0.31 1.4 I 
TPheT ND      
ND – not determined due to the solubility issues; not tox – compound not toxic in the 428 
available solubility range; ci – confidence intervals; SF – sensitivity factor calculated as  429 
a ratio of EC50 values obtained for mock versus Mate7 transfected cells;  430 
TOI – type of interaction 431 
 432 
Among widely used pesticides, we screened 14 substances of different chemical composition and showed for 433 
the first time interaction of any vertebrate Mate transporter with the organophosphate diazinon, and the 434 
triazine atrazine, albeit with rather low affinity (Fig. 3, Tables 4 and 5).  435 
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Out of almost 50 screened pharmaceuticals, interaction with Mate7 was observed for 20.  With exception of 436 
interaction data for verapamil, quinidine and mpp+ as shown in our previous paper (Loncar et al., 2016), in 437 
this study we report the first data on interaction of numerous pharmaceuticals with a fish Mate transporter. 438 
Acebutulol, methotrexate, estradiol, atorvastatin and fluoxetine have not been shown to interact with Mates, 439 
and herewith we suggest that Mate7 transports acebutolol, and is inhibited by the other four. The results 440 
previously reported for procainamide and ranitidine are in line with our findings, while the result for the 441 
pramipexole is in contradiction to our indication of its non-competitive inhibition of zebrafish Mate7 (Ivanyuk 442 
et al., 2017).  Tetracycline and verapamil inhibit zebrafish Mate7, however there is no indication of transport 443 
which is similar to human MATE1. We showed that imipramine, propranolol, diphenhydramine, 444 
pyrimethamine and doxorubicin are competitive inhibitors (substrates) while for human MATEs only inhibition 445 
has been shown (Ivanyuk et al., 2017). Quinidine has been shown to be transported by human MATEs (Masuda 446 
et al., 2006; Sato et al., 2008), and diltiazem was shown to interact with human MATEs (Tsuda et al., 2009). 447 
Our results suggest that both are non-competitive inhibitors i.e. not transported by Mate7. Mitoxantrone and 448 
sildenafil are non-competitive inhibitors of both zebrafish Mate7 and human MATE1 (Meyer zu Schwabedissen 449 
et al., 2010; Wittwer et al., 2013). Likewise, we show that tetracycline, pramipexole, fluoxetine, methotrexate, 450 
verapamil, estradiol, and atorvastatin all belong to the group of non-competitive inhibitors.  451 
Similar to tested industrial substances, considering effective inhibitory concentrations of pharmaceuticals 452 
found in our study, it is not clear whether inhibition of zebrafish Mate7 transport by these substances has any 453 
physiological, pharmacological or environmental relevance? Although definitive answers to these questions 454 
should be addressed by follow up in vivo studies preferably done with zebrafish Mate7 knockouts, our in vitro 455 
experiments aimed at modulation of cytotoxicity offer some initial insights. As shown in Fig. 6, when stable 456 
zebrafish Mate7 transfectants were coexposed with DAPI as the model toxic substance and Mate7 substrate 457 
in combination with verapamil or quinidine as identified non-competitive inhibitors, a clear rescue from DAPI 458 
cytotoxicity and shifts in related dose-response curves were observed in comparison to mock cells. 459 
Consequently, as result of lower DAPI uptake transfected cells became 5-10 times more resistant compared 460 
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to the cells exposed to toxicant only and without inhibitors (Table S4). Therefore, these in vitro data point to 461 
possibility that modulation of the Mate7 transport function may also have toxicological relevance in vivo. 462 
Accordingly, some assumptions may be credibly formulated for the most potent and/or environmentally most 463 
relevant zebrafish Mate7 pharmaceutical interactors determined in this study. For example, although 464 
tetracyclines are persistent in aquatic environment, their maximal environmental concentrations are in ng/L 465 
range (Daghrir and Drogui, 2013) which is too low to excrete notable effect on Mate7. However, tetracycline 466 
is easily precipitated with cations as potassium, and accumulates in the sewage sludge and sediments 467 
(Daughton and Ternes, 1999). In addition, although data on tetracycline plasma concentrations in zebrafish 468 
are not available, maximal concentrations recorded in humans are in µM range which would be sufficient to 469 
modulate Mate7 activity. Sildenafil is a potent and selective inhibitor of cGMP-specific phosphodiesterase type 470 
5 used to treat erectile dysfunction and pulmonary arterial hypertension. It has been shown to competitively 471 
inhibit ABCB1 and ABCG2 at clinically achievable concentrations and reverse the efflux of paclitaxel, 472 
mitoxantrone and methotrexate in vitro (Shi et al., 2011; Stacy et al., 2013). Wittwer et al. (2013) showed that 473 
20 µM sildenafil inhibits human MATE1 transport of ASP+. In this study we demonstrated that sildenafil 474 
strongly inhibits Mate7 in non-competitive manner, implying it could impair Mate7 protective or physiological 475 
function.  476 
Mitoxantrone is an antineoplastic agent that has been shown to interact with human MATE1 at IC50 values 477 
similar to those we determined for zebrafish Mate7 (Meyer zu Schwabedissen et al., 2010; Grottker et al., 478 
2011). The peak plasma concentration reported in vivo for mitoxantrone is 0.6 µM (Brunton et al., 2008; Meyer 479 
zu Schwabedissen et al., 2010). It has also been shown to interact with zebrafish Oct1 uptake transporter (IC50 480 
85 µM). Mitoxantrone does not influence trout Abcg2a ATPase activity while it has been shown to be 481 
transported by human ABCB1 and ABCG2 (Sarkadi et al., 2006; Zaja et al., 2016).  482 
Both human MATEs have been shown to transport pramipexole (Knop et al., 2015; Ivanyuk et al., 2017). Our 483 
results show that pramipexole (IC50 21 µM) strongly inhibits zebrafish Mate7 which is also supported by toxicity 484 
data. There are several possible explanations for the observed discrepancy between zebrafish Mate7 and 485 
human MATEs. Tsuda et al. (2009) reported that pramipexole has much higher affinity for human MATE2-K 486 
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than for MATE1, and since zebrafish has at least 5 functional Mate transporters it could be that some of the 487 
other four, and not Mate7, transports pramipexole. Knop et al. (2015) showed that pramipexole uptake by 488 
human MATE1 is much lower than transcellular efflux by the same transporter. They speculate this could be 489 
due to the different affinity for MATE1 in extracellular versus intracellular space, i.e. the affinity is not the 490 
same on the both sides of membrane. Finally, it could be that the difference is species related.  491 
Verapamil, calcium channel blocker used as antiarrhythmic agent, inhibits both human MATEs (Tanihara et al., 492 
2007) and supposedly is being transported by MATE2-K (Masuda et al., 2006). It is a substrate of OCT2 and 493 
ABCB1 (Ivanyuk et al., 2017). Its peak in vivo concentration has been reported to be 0.55 µM (Brunton et al., 494 
2008). It inhibits zebrafish Oct1 at IC50 of 14 µM (Mihaljevic et al., 2017), and our results indicate that verapamil 495 
is a strong inhibitor of zebrafish Mate7 (IC50 3.0 µM).  496 
Quinidine, a sodium and potassium channel blocker used as antiarrhythmic agent, is transported by both 497 
human MATE1 (Sato et al., 2008) and MATE2-K (Masuda et al., 2006). It is also transported by human ABCB1 498 
and OCT2, but it does not interact with ABCG2 or ABCC2 (Ivanyuk et al., 2017). Zebrafish Oct1 (IC50 140 µM) 499 
has 20 times lower affinity for quinidine than Mate7 (IC50 6.0 µM).  The peak plasma concentration of 3.7 µM 500 
(2.9 mg/l) has been reported for quinidine sulphate (Brunton et al., 2008). Acute ecotoxicology data for 501 
quinidine are available for several aquatic species, with EC50 values ranging from 8.3 - 274 mg/l (Webb, 2004). 502 
Our assays showed quinidine to be a potent non-competitive inhibitor of Mate7. 503 
The second group of pharmaceutical substances are those identified in this study as zebrafish Mate7 504 
substrates: propranolol, acebutolol, procainamide, ranitidine, imipramine, DPH, diazinon, MPP, doxorubicin, 505 
and pyrimethamine. Propranolol has been shown to strongly interact with human MATEs (IC50 8 µM) (Astorga 506 
et al., 2012). It inhibits human ABCB1 activity but is not transported (Bachmakov et al., 2006). Stott et al. (2015) 507 
have shown using primary trout gill cell culture that efflux of propranolol or its metabolites is pH dependent 508 
and increases with extracellular acidification from pH 8 to pH 6. They used propranolol concentration that is 509 
close to environmentally reported values (4 nM or 1 µg/L), and actually speculated that the observed, pH 510 
dependent efflux, might be due to the activity of an exporter present in gill that is not a member of the ABC 511 
family. Mate7 present in the zebrafish gill tissue may explain active efflux of propranolol observed in the trout, 512 
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as we show here that propranolol is a strong competitive inhibitor (IC50 19.7 µM), i.e. the substrate of zebrafish 513 
Mate7. Unfortunately, the finding could not be further supported with toxicological experiment due to lack of 514 
toxicity (MTT assay) in the range of specific transport.  515 
Imipramine has been shown to interact with human MATEs with IC50 values between 40 and 200 µM (Tsuda 516 
et al. 2009). Stott et al. (2015) showed that imipramine uptake in trout gill cells is mediated via carrier process. 517 
Our results indicate that imipramine is transported by Mate7 with high affinity (IC50 = 28 µM). Maximal 518 
recorded environmental concentration of imipramine is 0.4 pM (0.14 ng/l) (Stott et al., 2015), and in plasma 519 
it reaches concentration of 0.6 µM (200 µg/l) (Brunton et al., 2008). 520 
Doxorubicin is an anthracycline antibiotic used as chemotherapeutic agent. Its therapeutic dose could go up 521 
to 1.75 µM (950 µg/l) (Brunton et al., 2008). Inhibition of human MATE1 has been shown (Wittwer et al., 2013), 522 
but transport has not been verified. We show that doxorubicin is a high affinity competitive inhibitor (IC50 14.4 523 
µM), as is further supported by results of our toxicity modulation experiments (Table 5). 524 
Pyrimethamine, a folic acid antagonist used as an antimalarial agent, has been reported as the potent inhibitor 525 
of both human MATEs (Ito et al., 2010). Our results indicate that pyrimethamine is a high affinity competitive 526 
inhibitor of zebrafish Mate7 (IC50 15 µM). Clinical concentrations of pyrimethamine are in lower micromolar 527 
range (2.3 µM) (Kusuhara et al., 2011) while in the environment maximal concentration of 0.2 nM (60 ng/l) 528 
has been reported (Azzouz and Ballesteros, 2013). 529 
In summary, in this study we developed an effective high throughput screening assay for identification and 530 
initial characterization (substrates versus non-competitive inhibitors) of zebrafish Mate7 interactors, 531 
demonstrated its usability by screening a wide range of environmentally relevant substances, and reported 532 
the first data on identification of potent Mate7 inhibitors and/or substrates among tested substances. 533 
Interaction with any vertebrate Mate transporter has been shown for the first time for a series of industrial 534 
compounds, pesticides, and pharmaceuticals. Some of the inhibitors identified could be of environmental 535 
concern. They may potentially impair normal Mate7 efflux function and thus decrease the fish defence 536 
capacity against environmental contaminants, or interfere with transport of yet unidentified physiological 537 
substrates.  538 
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In addition, based on the data obtained in this study it appears there are significant differences between 539 
zebrafish Mate7 and mammalian Mates’ substrate preferences, a finding that should be taken into 540 
consideration when using zebrafish as a model organism in pharmacological and toxicokinetics studies. Finally, 541 
identifying drugs that may inhibit Mates is important for predicting drug-drug interactions that may lead to 542 
nephrotoxicity through increase in drug accumulation as a consequence of transporter(s) inhibition.  543 
 544 
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